One of Roche’s spot­light PhI­II can­cer drug hope­fuls stum­bles in a key tri­al, with hit-and-miss re­sults

Roche’s can­cer team at Genen­tech has turned a few cards on their Phase III prostate can­cer study for the AKT block­er ipatasert­ib, and they’re not all good to hold.

The Genen­tech crew spot­light­ed the pos­i­tive, high­light­ing a suc­cess on pro­gres­sion-free sur­vival in metasta­t­ic cas­tra­tion-re­sis­tant pa­tients with PTEN loss. But the drug — de­liv­ered in com­bi­na­tion with the stan­dard of care com­bo abi­raterone and pred­nisone/pred­nisolone com­pared to a SOC con­trol arm — failed on PFS for the over­all group in the IPATen­tial150 tri­al, their oth­er co-pri­ma­ry end­point.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN